Implementation of a HUB-and-spoke telestroke network to improve access to intravenous thrombolysis in Indonesia: A retrospective cohort study
In brief
Telestroke patients received clot-busting drugs more often: 27% versus 4%
In a retrospective study in Greater Bandung, Indonesia, 8 of 30 ischemic stroke patients assessed through a telestroke network received intravenous clot-busting treatment, compared with 6 of 164 on the conventional referral pathway. The telestroke group also reached the hub sooner, but the small, nonrandomized comparison cannot show that the network caused better treatment access or outcomes.
- Journal
- Telemedicine reports (Q2)
- Published
- 8 October 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 4, Very Low (CEBM 4)
- Authors
- Lisda Amalia, Fathul Huda, Cep Juli, Abdurahman Harits, Deidre Anne De Silva
- PMID
- 43048112
- DOI
- 10.1177/26924366261493728
Why clinicians should know about it
- Picked for Health Informatics (top studies of the week, 22 November 2026): Real-world telestroke network implementation and care-process evaluation
Abstract
BACKGROUND: Access to specialist-supported hyperacute stroke care remains limited in many regions of Indonesia. Telestroke may facilitate remote neurological assessment, interpretation of neuroimaging, reperfusion decision-making, and coordination of referral to comprehensive stroke centres. We evaluated the early implementation of a hub-and-spoke telestroke network in the Greater Bandung metropolitan area and described its observed treatment processes and clinical outcomes. METHODS: We conducted a retrospective cohort study of patients evaluated through a five-spoke telestroke network connected to Hasan Sadikin Central General Hospital (RSHS), Bandung, between May 2024 and January 2025. Patients receiving formal telestroke consultation were classified according to their final diagnosis and clinical pathway. The final telestroke analytic cohort included patients meeting the prespecified study criteria; stroke mimics were excluded from the comparative stroke cohort. Intravenous thrombolysis was analyzed using an ischemic-stroke-specific denominator. Demographic characteristics, stroke severity, referral times, reperfusion treatment, and neurological outcomes were assessed. Continuous variables were summarized as mean ± standard deviation or median (interquartile range), as appropriate, and categorical variables as n/N (%). Effect estimates with 95% confidence intervals were reported where appropriate. RESULTS: Forty patients were identified in the telestroke database during the study period. One patient with a stroke mimic was excluded, resulting in 39 patients in the final telestroke analytic cohort, including 30 patients with ischemic stroke and 9 with intracerebral hemorrhage. Patients managed through the telestroke pathway had a substantially shorter median onset-to-hub interval than those managed through the conventional referral pathway (3.5 hours [IQR 2.5-6.0] vs. 20.0 hours [IQR 7.0-72.0]; p<0.001). Among patients with ischemic stroke, intravenous thrombolysis was administered in 8/30 patients (26.7%) in the telestroke pathway and 6/164 patients (3.7%) in the conventional referral pathway. The observed odds of intravenous thrombolysis were higher in the telestroke pathway (OR 9.58, 95% CI 3.04-30.20; p<0.001). The telestroke group also demonstrated a greater median reduction in NIHSS during hospitalization (ΔNIHSS 3 [IQR 2-5] vs. 1 [IQR 0-4]; p<0.001). CONCLUSION: Implementation of a hub-and-spoke telestroke network was feasible in the Greater Bandung metropolitan area and provided a structured pathway for specialist stroke consultation, reperfusion assessment, and referral coordination. The observed differences in referral time and intravenous thrombolysis utilization suggest potential process-level advantages, but these findings should be interpreted cautiously because of the retrospective design, small telestroke cohort, and substantial differences between the participating and comparator hospital pathways. Prospective multicentre evaluation is required to determine the effectiveness and generalizability of the model.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.